Mark Kendall | |
|---|---|
| Born | 16 April 1972 |
| Nationality | Australian |
| Occupation | Biomedical engineer |
| Employer | Australian National University |
| Known for | Biomedical invention |
Mark A. F. Kendall (BE PhD FTSE FRSA FNAI) (born 1972) is an Australian biomedical engineer, inventor, scientist and entrepreneur.
He is Founder and CEO of WearOptimo Pty Ltd [1] and the Vice-Chancellor's Entrepreneurial Professor at the Australian National University. [2]
Kendall was formerly the Professor of Biomedical Engineering at the University of Queensland, where he led a team at the Australian Institute for Bioengineering and Nanotechnology[ citation needed ]. He was Founder, CTO and a Director of Vaxxas[ citation needed ]. Prior to this, in the UK, he was a University Research Lecturer at the University of Oxford and a lecturer at Magdalen College, Oxford [ citation needed ]. Whilst at Oxford, Kendall was Associate Director of the PowderJect Research Centre for Gene and Drug Delivery[ citation needed ].
Kendall serves at the co-chair of the $150 million Australian Stem Cell Therapies Mission [3] and on the World Economic Forum Global Future Council on Biotechnology. [4]
Kendall has filed more than 160 patents (including territories)[ citation needed ], published in excess of 300 papers[ citation needed ], licensed his technologies seven times (including to Merck & Co.)[ citation needed ] and partnered globally, including with the World Health Organization, and the Bill & Melinda Gates Foundation. [5] The biotech enterprises he has founded or made significant contribution to have generated in the region of $2 billion Aus in value[ citation needed ].
Kendall's contributions to innovation in global healthcare has been recognised with more than forty awards. These include recent elections as:
• World Economic Forum Technology Pioneer (2015). [6]
• Fellow of ATSE; Australian Academy of Technological Sciences and Engineering (2017). [7]
• Fellow of the Royal Society for the encouragement of Arts, Manufacture and Commerce (now the RSA), UK; (2017)[ citation needed ].
Kendall is a CSL Young Florey Medallist [8] and Rolex Laureate. [9] [10]
Kendall's work regularly features in international media, including on the National Geographic Channel. [11]
Kendall's TedGlobal talk has been viewed more than a million times. [12]
Kendall was born on 16 April 1972. [13] He received his Bachelors of Engineering (Hons I, 1993) and PhD (1998) from the University of Queensland. [14]
In 1998, Kendall moved to the UK to take up a position in the Department of Engineering Science at the University of Oxford (1998-2006). He has subsequently held positions at the University of Queensland (2006-2018)[ citation needed ] and at the Australian National University (2018–Present)[ citation needed ].
Kendall has over 160 patent applications of which[ citation needed ], 128 have been granted to date[ citation needed ]. He has authored more than 300 refereed papers[ citation needed ].
At the University of Oxford [14] (1998-2006) Kendall developed a biolistic technique for the delivery of vaccines directly into the skin without the use of needles.
At the University of Queensland (2006-2018) Kendall invented the Nanopatch [15] [16] for needle-free delivery of vaccines. [17] [18]
At WearOptimo [19] and the Australian National University [20] (2018 to present), Kendall has invented the Microwearable™ [21] [22] sensor for personalised medicine.
During his career, Kendall has collaborated with major global health partners including the Bill & Melinda Gates Foundation, [23] World Health Organization [24] [25] and Merck & Co. [26]
He is an Australian Government Academy of Science COVID-19 Expert. [27]
As Associate Director of the Oxford University PowderJect Research Centre (2000-2006)[ citation needed ], Kendall advanced biolistics technology[ citation needed ], commercialised with PowderJect[ citation needed ], purchased by Chiron (later Novartis) in 2003[ citation needed ]; and then with PowderMed, purchased by Pfizer in 2006[ citation needed ].
Kendall founded Vaxxas in 2011 to advance his Nanopatch [15] technology for global impact, securing more than $40 million of investment, in the series A ($15m) [37] and B (in excess of $25m) rounds. [38] The Nanopatch technology has been licensed to Merck & Co. He served as the Vaxxas Chief Technology Officer, Director, and Chair of the Vaxxas Advisory Board (2011-2015).
In 2018, Kendall founded WearOptimo [39] where he serves as CEO.
{{cite web}}: |first= has generic name (help){{cite web}}: CS1 maint: numeric names: authors list (link){{cite web}}: CS1 maint: numeric names: authors list (link)